SCHEMBL4050203

SCHEMBL4050203

FC(F)(F)c1cccc(-c2n[c]n[nH]2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN2A Q99250 2/20 0.51
HRH1 P35367 1/20 0.47
HRH4 Q9H3N8 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
THRB P10828 1/20 0.46
CYP2C9 P11712 1/20 0.46
PKM P14618 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
STAT6 P42226 1/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HIF1A Q16665 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4050332 0.80 GFER (0.46) SCN2AKDM4ENPC1RAB9ANOTUM
SCHEMBL4044116 0.78 MGAM (0.42) SMN1; SMN2NOTUMIDO1PIN1GRK6
SCHEMBL4048612 0.75 HSD17B1 (0.46) ALDH1A1CYP1A2CYP3A4CYP2C9HSD17B10
SCHEMBL4050892 0.75 DCUN1D1 (0.49) HRH1HRH4KDM4EMEN1NPC1
SCHEMBL4046435 0.75 IDO1 (0.53) SCN2AHRH1KDM4EALDH1A1NOTUM
SCHEMBL4015570 0.74 SCN2A (0.55) SCN2AHRH1HRH4KDM4EMEN1
SCHEMBL1436077 0.73 SCN2A (0.54) SCN2AHRH1HRH4KDM4EMEN1
SCHEMBL703748 0.72 SCN2A (0.53) SCN2AHRH1HRH4KDM4EMEN1
SCHEMBL29678302 0.72 TSHR (0.58) SCN2AALDH1A1TSHRNOTUMIDO1
SCHEMBL1263144 0.72 TSHR (0.58) SCN2AALDH1A1TSHRNOTUMIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1144384-A1 COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 Elan Pharmaceuticals, Inc. (US) 2001-10-17 EP claimed
WO-2000043369-A1 COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARMACEUTICALS, INC. (US) 2000-07-27 WO claimed
US-7589096-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-15 US disclosed
EP-1566384-B1 NOVEL AZOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2009-06-17 EP disclosed
US-20080188507-A1 Novel azole derivatives MSD K.K. (JP) 2008-08-07 US disclosed
US-7365079-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-29 US disclosed
US-20060111380-A1 Novel azole derivatives MSD K.K. (JP) 2006-05-25 US disclosed
EP-1566384-A1 NOVEL AZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188507-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R SCN2A 3786/4885HRH1 699/4885HRH4 335/4885
US-20060111380-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R SCN2A 3760/4885HRH1 761/4885HRH4 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.